A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis

Takeshi Tomoda; Hironari Kato; Sho Mizukawa; Shinichiro Muro; Yutaka Akimoto; Daisuke Uchida; Kazuyuki Matsumoto; Naoki Yamamoto; Shigeru Horiguchi; Koichiro Tsutsumi; Hiroyuki Okada

A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis

Takeshi Tomoda, Hironari Kato, Sho Mizukawa, Shinichiro Muro, Yutaka Akimoto, Daisuke Uchida, Kazuyuki Matsumoto, Naoki Yamamoto, Shigeru Horiguchi, Koichiro Tsutsumi, Hiroyuki Okada

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP). A preliminary research suggested that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more effectively than NSAIDs alone. We conduct a two-arm, multicenter, prospective, randomized, superiority trial to evaluate the additional effect of nitroglycerin for prevention of PEP. A total of 900 patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate sublingual tablet. The primary endpoint is the occurrence of PEP. This study will clarify whether NSAIDs plus nitroglycerin can prevent PEP.

Original language	English
Pages (from-to)	405-408
Number of pages	4
Journal	Acta medica Okayama
Volume	70
Issue number	5
Publication status	Published - 2016

Keywords

NSAIDs
Nitroglycerin
Post-ERCP pancreatitis

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tomoda, T., Kato, H., Mizukawa, S., Muro, S., Akimoto, Y., Uchida, D., Matsumoto, K., Yamamoto, N., Horiguchi, S., Tsutsumi, K., & Okada, H. (2016). A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis. Acta medica Okayama, 70(5), 405-408.

A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis. / Tomoda, Takeshi; Kato, Hironari; Mizukawa, Sho et al.
In: Acta medica Okayama, Vol. 70, No. 5, 2016, p. 405-408.

Research output: Contribution to journal › Article › peer-review

Tomoda, T, Kato, H, Mizukawa, S, Muro, S, Akimoto, Y, Uchida, D , Matsumoto, K, Yamamoto, N, Horiguchi, S , Tsutsumi, K & Okada, H 2016, 'A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis', Acta medica Okayama, vol. 70, no. 5, pp. 405-408.

@article{924a07163bac466eb49c8527c387fdd6,

title = "A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis",

abstract = "Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP). A preliminary research suggested that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more effectively than NSAIDs alone. We conduct a two-arm, multicenter, prospective, randomized, superiority trial to evaluate the additional effect of nitroglycerin for prevention of PEP. A total of 900 patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate sublingual tablet. The primary endpoint is the occurrence of PEP. This study will clarify whether NSAIDs plus nitroglycerin can prevent PEP.",

keywords = "NSAIDs, Nitroglycerin, Post-ERCP pancreatitis",

author = "Takeshi Tomoda and Hironari Kato and Sho Mizukawa and Shinichiro Muro and Yutaka Akimoto and Daisuke Uchida and Kazuyuki Matsumoto and Naoki Yamamoto and Shigeru Horiguchi and Koichiro Tsutsumi and Hiroyuki Okada",

note = "Publisher Copyright: {\textcopyright} 2016 by Okayama University Medical School.",

year = "2016",

language = "English",

volume = "70",

pages = "405--408",

journal = "Acta medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "5",

}

TY - JOUR

T1 - A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis

AU - Tomoda, Takeshi

AU - Kato, Hironari

AU - Mizukawa, Sho

AU - Muro, Shinichiro

AU - Akimoto, Yutaka

AU - Uchida, Daisuke

AU - Matsumoto, Kazuyuki

AU - Yamamoto, Naoki

AU - Horiguchi, Shigeru

AU - Tsutsumi, Koichiro

AU - Okada, Hiroyuki

PY - 2016

Y1 - 2016

N2 - Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP). A preliminary research suggested that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more effectively than NSAIDs alone. We conduct a two-arm, multicenter, prospective, randomized, superiority trial to evaluate the additional effect of nitroglycerin for prevention of PEP. A total of 900 patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate sublingual tablet. The primary endpoint is the occurrence of PEP. This study will clarify whether NSAIDs plus nitroglycerin can prevent PEP.

AB - Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP). A preliminary research suggested that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more effectively than NSAIDs alone. We conduct a two-arm, multicenter, prospective, randomized, superiority trial to evaluate the additional effect of nitroglycerin for prevention of PEP. A total of 900 patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate sublingual tablet. The primary endpoint is the occurrence of PEP. This study will clarify whether NSAIDs plus nitroglycerin can prevent PEP.

KW - NSAIDs

KW - Nitroglycerin

KW - Post-ERCP pancreatitis

UR - http://www.scopus.com/inward/record.url?scp=84997684112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997684112&partnerID=8YFLogxK

M3 - Article

C2 - 27777436

AN - SCOPUS:84997684112

SN - 0386-300X

VL - 70

SP - 405

EP - 408

JO - Acta medica Okayama

JF - Acta medica Okayama

IS - 5

ER -

A multicenter, prospective, randomized controlled trial evaluating the efficacy of rectal diclofenac and sublingual nitroglycerin as a combined prophylactic treatment for post-ERCP pancreatitis

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this